LC

Lucia Cinque

Co-founder & Chief Of Staff at WhiteLab Genomics

Lucia Cinque has a diverse work experience spanning multiple industries and roles. Lucia is currently serving as the Chief Innovation Officer & Managing Director at Wörwag Pharma GmbH & Co. KG. Prior to this, they co-founded and served as a board member at WhiteLab Genomics (YC W22). Lucia also held the position of VP Product & Innovation at ENDODIAG from June 2018 to May 2021. Lucia contributed to the growth and development of Apricity as Digital Product Strategy & Management from December 2020 to April 2021. Lucia Cinque has also worked at Genomic Vision in various capacities, including Director Product & Innovation, Product Innovation & Marketing Leader, Intellectual Property & Intelligence Manager, and R&D Project Manager. Lucia started their career with a research traineeship at Philips Research High Tech Campus in the Health Care Department.

Lucia Cinque completed a Ph.D. in DNA Biophysics, Microfluidics, and DNA Repair at Ecole normale supérieure from 2007 to 2011. Before that, they obtained a Master of Science degree in Biomedical Engineering from Politecnico di Milano, which they pursued from 2004 to 2006. Prior to their time at Politecnico di Milano, they also completed a Master of Science degree in Biomedical Engineering at Polytechnique Montréal from 2004 to 2005.

Location

Paris, France

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


WhiteLab Genomics

WhiteLab Genomics develops a proprietary platform that leverages graph knowledge technology and machine learning to help companies discover and design new genomic therapies. WhiteLab Genomics enables genomic medicine scientists to obtain precise and comprehensive answers to key scientific and technological questions such as optimizing payload andvector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. Whitelab Genomics guides its clients through the in-silico development phases, allowing them to quickly develop target vectors and payloads while saving valuable time needed to provide patients with access to new genomic therapies.


Industries

Employees

11-50

Links